Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B56844dc98a6ac9b94fd833f32066ab6f> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B56844dc98a6ac9b94fd833f32066ab6f NCIT_P378 "NCI" @default.
- B56844dc98a6ac9b94fd833f32066ab6f type Axiom @default.
- B56844dc98a6ac9b94fd833f32066ab6f annotatedProperty IAO_0000115 @default.
- B56844dc98a6ac9b94fd833f32066ab6f annotatedSource NCIT_C153259 @default.
- B56844dc98a6ac9b94fd833f32066ab6f annotatedTarget "An agonistic hexamer formation-enhanced mixture of two antibodies (HexaBody) that target two separate epitopes on death receptor type 5 (DR5; TNFRSF10B; tumor necrosis factor-related apoptosis-inducing ligand receptor 2; TRAILR2), with potential antineoplastic activity. Upon administration, tilogotamab specifically binds to and activates DR5. This results in the activation of caspase cascades and the induction of apoptosis in DR5-expressing tumor cells. DR5, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is involved in the promotion of caspase-dependent apoptosis. Compared to other DR5 antibody-based agonists, the antibodies in GEN1029 (DR5-01 and DR5-05) elicit increased receptor activation because they exhibit enhanced formation of antibody hexamers and receptor clusters at the cell surface due to E430G mutations in the Fc domains of both antibodies." @default.